 Scopus BioPharma NASDAQ:SCPS shares are trading higher after the company announced the FDA has approved its IND application for CpG-STAT3siRNA, the companys distinctive immuno-oncology RNA therapy for the treatment of multiple cancers. Scopus BioPharmas stock has been rising Monday, up 102.07 to a price of 11.6. 